

Robert P Hirten

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6214653/publications.pdf>

Version: 2024-02-01

48
papers

1,702
citations

361296

20
h-index

302012

39
g-index

52
all docs

52
docs citations

52
times ranked

2705
citing authors

#	ARTICLE	IF	CITATIONS
1	Adherent-invasive <i>Escherichia coli</i> in inflammatory bowel disease. <i>Cut</i> , 2018, 67, 574-587.	6.1	366
2	Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. <i>American Journal of Gastroenterology</i> , 2018, 113, 1345.	0.2	119
3	Gut microbiota density influences host physiology and is shaped by host and microbial factors. <i>ELife</i> , 2019, 8, .	2.8	118
4	Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 155, 687-695.e10.	0.6	93
5	Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1374-1384.	2.4	91
6	Use of Physiological Data From a Wearable Device to Identify SARS-CoV-2 Infection and Symptoms and Predict COVID-19 Diagnosis: Observational Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e26107.	2.1	91
7	Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1533-1540.e2.	2.4	60
8	New Therapeutics for Ulcerative Colitis. <i>Annual Review of Medicine</i> , 2021, 72, 199-213.	5.0	52
9	Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2461-2467.	0.9	50
10	Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 669-681.	1.9	48
11	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2952-2961.e8.	2.4	48
12	Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2497-2505.e1.	2.4	44
13	Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium Difficile in Patients With and Without Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 969-979.	0.9	38
14	Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2015, 110, 1737-1738.	0.2	37
15	Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 126-135.	2.4	32
16	The Management of Intestinal Penetrating Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 752-765.	0.9	31
17	Review article: bacteriophages in gastroenterology—from biology to clinical applications. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 53-63.	1.9	31
18	Anastomotic Ulcers After Ileocolic Resection for Crohn's Disease Are Common and Predict Recurrence. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1050-1058.	0.9	27

#	ARTICLE	IF	CITATIONS
19	Autoimmune and Chronic Inflammatory Disease Patients with COVID-19. <i>ACR Open Rheumatology</i> , 2021, 3, 111-115.	0.9	25
20	Fecal Microbiota Transplant for Recurrent <i>Clostridium difficile</i> Infection in Pediatric Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2019, 68, 343-347.	0.9	23
21	Diffusion and perfusion MRI quantification in ileal Crohn's disease. <i>European Radiology</i> , 2019, 29, 993-1002.	2.3	22
22	Endoscopic activity in asymptomatic patients with an ileal pouch is associated with an increased risk of pouchitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1189-1194.	1.9	22
23	Longitudinal Autonomic Nervous System Measures Correlate With Stress and Ulcerative Colitis Disease Activity and Predict Flare. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1576-1584.	0.9	22
24	Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2207-2209.e3.	2.4	20
25	The Role of Resilience in Irritable Bowel Syndrome, Other Chronic Gastrointestinal Conditions, and the General Population. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 19, 2541-2550.e1.	2.4	18
26	Emergent colectomy rates decreased while elective ileal pouch rates were stable over time: a nationwide inpatient sample study. <i>International Journal of Colorectal Disease</i> , 2019, 34, 1771-1779.	1.0	16
27	Factors Associated With Longitudinal Psychological and Physiological Stress in Health Care Workers During the COVID-19 Pandemic: Observational Study Using Apple Watch Data. <i>Journal of Medical Internet Research</i> , 2021, 23, e31295.	2.1	15
28	Clinical updates on perianal fistulas in Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 597-605.	1.4	14
29	Wearable Devices Are Well Accepted by Patients in the Study and Management of Inflammatory Bowel Disease: A Survey Study. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1836-1844.	1.1	14
30	Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 257-258.	2.4	12
31	Vedolizumab therapy in common variable immune deficiency associated enteropathy: A case series. <i>Clinical Immunology</i> , 2020, 212, 108362.	1.4	12
32	Use of digital cholangioscopy in a dilated bile duct for detection of small symptomatic bile duct stones. <i>Gastrointestinal Endoscopy</i> , 2016, 84, 372.	0.5	11
33	Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1854-1861.	0.9	11
34	Endoscopic ultrasound-guided fine-needle aspiration of solid lesions on clopidogrel may not be a high-risk procedure for bleeding: A case series. <i>Digestive Endoscopy</i> , 2016, 28, 216-219.	1.3	9
35	A User's Guide to De-escalating Immunomodulator and Biologic Therapy in Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1336-1345.	2.4	9
36	Ileocolic anastomotic inflammation after resection for Crohn's disease indicates disease recurrence: a histopathologic study. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 795-799.	0.6	9

#	ARTICLE	IF	CITATIONS
37	Evaluation of a machine learning approach utilizing wearable data for prediction of SARS-CoV-2 infection in healthcare workers. <i>JAMIA Open</i> , 2022, 5, .	1.0	9
38	Current Trends in IBD—Development of Mucosal-Based Biomarkers and a Novel Minimally Invasive Recoverable Sampling System. <i>Inflammatory Bowel Diseases</i> , 2021, 27, S17-S24.	0.9	6
39	Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1321-1331.	0.9	5
40	Need for Caution in Diagnosis of Irritable Bowel Syndrome in Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1315.	2.4	3
41	Identification of volumetric laser endomicroscopy features of colon polyps with histologic correlation. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 1558-1564.	0.5	3
42	EUS-Guided Botulinum Toxin Injection of the Internal Anal Sphincter in Anorectal Outlet Obstruction. <i>American Journal of Gastroenterology</i> , 2014, 109, 1293-1294.	0.2	2
43	Novel Targets For Therapeutic Intervention in Inflammatory Bowel Disease. What is the Best Way to Assess the Safety Profile of a Drug?. <i>Current Pharmaceutical Design</i> , 2019, 25, 57-63.	0.9	2
44	Autoimmune conditions in the World Trade Center general responder cohort: A nested case-control and standardized incidence ratio analysis. <i>American Journal of Industrial Medicine</i> , 2022, 65, 117-131.	1.0	2
45	The Uncertain Role of Immunomodulator Maintenance After Cessation of Anti-Tumor Necrosis Factor ± Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1551-1552.	2.4	0
46	Unusual Cause of Fever and Abdominal Pain: Acute Suppuration of the Pancreas Duct and Endoscopic Management. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, e14-e15.	2.4	0
47	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 796-797.	2.4	0
48	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1301-1302.	2.4	0